SCHEMBL559945

SCHEMBL559945

Nc1cc([C@@H]2CNC(=O)C2)c(Br)cc1Cl

nearest known ligand 0.39

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MTNR1A P48039 2/20 0.39
ALDH1A1 P00352 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2C19 P33261 1/20 0.38
PDE4A P27815 7/20 0.35
PDE4B Q07343 3/20 0.35
PDE4C Q08493 3/20 0.35
PDE4D Q08499 3/20 0.35
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
TSHR P16473 1/20 0.32
GAA P10253 1/20 0.31
MAP4K1 Q92918 1/20 0.30
PKM P14618 1/20 0.30
PIK3CD O00329 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL559960 0.78 ALDH1A1 (0.45) MTNR1AALDH1A1CYP1A2CYP2C19PDE4A
SCHEMBL560175 0.76 MTNR1A (0.48) MTNR1AALDH1A1CYP1A2CYP2C19PDE4A
SCHEMBL559712 0.73 MTNR1A (0.48) MTNR1AALDH1A1CYP1A2CYP2C19PDE4A
SCHEMBL559921 0.73 PDE4A (0.52) ALDH1A1CYP1A2CYP2C19PDE4APDE4B
Hydrochloric Acid SCHEMBL560453 0.72 MTNR1A (0.47) MTNR1AALDH1A1CYP1A2CYP2C19PDE4A
SCHEMBL560015 0.70 PDE4A (0.52) ALDH1A1CYP1A2CYP2C19PDE4APDE4B
SCHEMBL23778971 0.68 MTNR1A (0.61) MTNR1AALDH1A1CYP1A2CYP2C19PDE4A
SCHEMBL10759562 0.68 MTNR1A (0.61) MTNR1AALDH1A1CYP1A2CYP2C19TSHR
SCHEMBL20177579 0.68 KDM1A (0.44) MTNR1AALDH1A1CYP1A2CYP2C19PDE4A
SCHEMBL18590493 0.67 MTNR1A (0.48) MTNR1AALDH1A1CYP1A2CYP2C19PDE4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8344028-B2 Gamma-amino-butyric acid derivatives as GABAB receptor ligands XENOPORT, INC. (US) 2013-01-01 US disclosed
EP-2419401-A2 GAMMA-AMINO-BUTYRIC ACID DERIVATIVES AS GABAb RECEPTOR LIGANDS XenoPort, Inc. (US) 2012-02-22 EP disclosed
US-20120035139-A9 GAMMA-AMINO-BUTYRIC ACID DERIVATIVES AS GABAB RECEPTOR LIGANDS XENOPORT, INC. 2012-02-09 US disclosed
US-20100267676-A1 GAMMA-AMINO-BUTYRIC ACID DERIVATIVES AS GABAB RECEPTOR LIGANDS XENOPORT, INC. 2010-10-21 US disclosed
WO-2010120370-A2 GAMMA-AMINO-BUTYRIC ACID DERIVATIVES AS GABAB RECEPTOR LIGANDS XENOPORT, INC. (US) 2010-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267676-A1 GAMMA-AMINO-BUTYRIC ACID DERIVATIVES AS GABAB RECEPTOR LIGANDS GABRB2, GABRB1, GABRB3 MTNR1A 394/4885ALDH1A1 1314/4885CYP1A2 1952/4885
US-20120035139-A9 GAMMA-AMINO-BUTYRIC ACID DERIVATIVES AS GABAB RECEPTOR LIGANDS GABRB2, GABRB1, GABRB3 MTNR1A 394/4885ALDH1A1 1314/4885CYP1A2 1952/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.